|
|
|
|
|
|
|
M T Wed Th F |
|
1 July, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amgen had discarded a T cell engager and returned it to the tiny California biotech that had developed it. Now, that company, 92Bio, has begun human trials in ovarian cancer in the US — bucking the China TCE trend. Kyle LaHucik has the details here. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
|
|
by Kyle LaHucik
|
A small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After... | |
|
|
|
|
|
|
by Kyle LaHucik
|
BridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the... | |
|
|
|
 |
|
Nate Fernhoff, Orca Bio CEO |
|
|
|
by Lei Lei Wu
|
The FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients. The therapy will be branded... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had... | |
|
|
|
|
|
|
|
